Choice of mobile phase: Implications for size exclusion chromatography-inductively coupled plasma-mass spectrometry analyses of copper, zinc and iron metalloproteins

Larissa Lago; Oliver RB Thomas; Blaine R Roberts

Journal article

Choice of mobile phase: Implications for size exclusion chromatography-inductively coupled plasma-mass spectrometry analyses of copper, zinc and iron metalloproteins

Larissa Lago, Oliver RB Thomas, Blaine R Roberts

Journal of Chromatography A | Elsevier | Published : 2020

DOI: 10.1016/j.chroma.2019.460806

Abstract

The correct identification of the metalloproteins present in human tissues and fluids is essential to our understanding of the cellular mechanisms underpinning a host of health disorders. Separation and analysis of biological samples are typically done via size exclusion chromatography hyphenated with inductively coupled plasma-mass spectrometry (SEC-ICP-MS). Although this technique can be extremely effective in identification of potential metalloproteins, the choice of mobile phase may have a marked effect on results, results by adversely affecting metal-protein bonds of the metalloproteins of interest. To assess the choice of mobile phase on SEC-ICP-MS resolution and the resulting metallop..

View full abstract

University of Melbourne Researchers

Ollie Thomas Author

Related Projects (1)

HARNESSING THE CONSEQUENCES OF IMPAIRED MITOCHONDRIAL ENERGY METABOLISM TO TREAT THE SYMPTOMS OF AGE-RELATED NEURONAL DECLINE

Cognitive function and locomotor ability decline due to advanced age and disorders such as motor neuron disease, Alzheimer’s and Parkinson’s..

Grants

Awarded by National Health and Medical Research Council

Awarded by NHMRC

Funding Acknowledgements

This work was supported by The Victorian Government's Operational Infrastructure Support Program and the Wicking Trust. Brain tissues were received from the Victorian Brain Bank, supported by The Florey Institute of Neuroscience and Mental Health, The Alfred Hospital, and the Victorian Institute of Forensic Medicine and funded in part by Parkinson's Victoria, MND Victoria, FightMND, Melbourne Dementia Research Centre, and Yulgilbar Foundation. We acknowledge funding and support; BR receives partial support from the National Health and Medical Research Council (1061550 & 1138673) and LL and BR from NHMRC grant number 1141592. BR receives support from Alzheimer's disease drug discovery foundation. BR receives research support from Agilent Technologies and e-MSion, Inc.